455 related articles for article (PubMed ID: 29268638)
1. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
Matera MG; Rogliani P; Calzetta L; Cazzola M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
[TBL] [Abstract][Full Text] [Related]
2. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab.
Cazzola M; Matera MG; Levi-Schaffer F; Rogliani P
Expert Opin Drug Saf; 2018 Apr; 17(4):429-435. PubMed ID: 29486600
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
4. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
Máspero J
Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
[TBL] [Abstract][Full Text] [Related]
5. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma.
Lim HF; Nair P
Expert Rev Respir Med; 2015 Apr; 9(2):135-42. PubMed ID: 25578680
[TBL] [Abstract][Full Text] [Related]
7. Update on reslizumab for eosinophilic asthma.
Cardet JC; Israel E
Expert Opin Biol Ther; 2015; 15(10):1531-9. PubMed ID: 26372797
[TBL] [Abstract][Full Text] [Related]
8. The safety of mepolizumab for the treatment of asthma.
Leung E; Al Efraij K; FitzGerald JM
Expert Opin Drug Saf; 2017 Mar; 16(3):397-404. PubMed ID: 28116937
[TBL] [Abstract][Full Text] [Related]
9. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.
Murphy K; Jacobs J; Bjermer L; Fahrenholz JM; Shalit Y; Garin M; Zangrilli J; Castro M
J Allergy Clin Immunol Pract; 2017; 5(6):1572-1581.e3. PubMed ID: 29122156
[TBL] [Abstract][Full Text] [Related]
10. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
11. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
[TBL] [Abstract][Full Text] [Related]
12. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
13. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
[TBL] [Abstract][Full Text] [Related]
14. Reslizumab in Eosinophilic Asthma: A Review.
Deeks ED; Brusselle G
Drugs; 2017 May; 77(7):777-784. PubMed ID: 28421429
[TBL] [Abstract][Full Text] [Related]
15. Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype.
Al Efraij K; FitzGerald JM
Expert Rev Clin Pharmacol; 2018 Jul; 11(7):669-676. PubMed ID: 29972739
[TBL] [Abstract][Full Text] [Related]
16. Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions.
Walsh GM
Curr Opin Mol Ther; 2009 Jun; 11(3):329-36. PubMed ID: 19479666
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment.
Bagnasco D; Heffler E; Testino E; Passalacqua G; Canonica GW
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):113-120. PubMed ID: 30632416
[TBL] [Abstract][Full Text] [Related]
18. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
19. Reslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
Brusselle G; Germinaro M; Weiss S; Zangrilli J
Pulm Pharmacol Ther; 2017 Apr; 43():39-45. PubMed ID: 28159511
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]